Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features.
[BACKGROUND] Familial pancreatic cancer (FPC) will be enriched for germline mutations (GLMs), particularly in homologous recombination repair (HRR) genes, but its distinction from sporadic pancreatic
- p-value p = 0.084
APA
Miura Y, Ohnami S, et al. (2026). Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features.. Annals of surgical oncology, 33(2), 1748-1759. https://doi.org/10.1245/s10434-025-18556-3
MLA
Miura Y, et al.. "Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features.." Annals of surgical oncology, vol. 33, no. 2, 2026, pp. 1748-1759.
PMID
41085800
Abstract
[BACKGROUND] Familial pancreatic cancer (FPC) will be enriched for germline mutations (GLMs), particularly in homologous recombination repair (HRR) genes, but its distinction from sporadic pancreatic cancer (PC) remains unclear.
[METHODS] We retrospectively analyzed 111 resected PCs, including 13 patients with FPC (11.8%) and 98 with non-FPC (88.2%). Whole-exome sequencing targeted 151 cancer-related genes, with parallel gene expression profiling. GLMs were assessed by ClinVar and in silico tools. Homologous recombination deficiency (HRD) scores, COSMIC signatures, immune deconvolution, and survival were compared.
[RESULTS] Patients with FPC and non-FPC were comparable in age, sex, tumor stage, and receipt of adjuvant chemotherapy. ClinVar-annotated GLMs were found in 2/13 patients with FPC (15.4%) and 4/98 patients with non-FPC (4.1%). FPC cases more often carried pancreatitis-associated variants (SPINK1, CFTR), whereas non-FPC included HRR-related variants (PALB2, FANCG). When potentially pathogenic HRR-related variants were considered together, prevalence was similar (23.1% vs. 12.2%, p = 0.380). HRD scores did not differ (median 22 vs. 19, p = 0.591), and high HRD scores (≥ 42) were observed only in two non-FPC cases, including one with PALB2. Differential expression analysis revealed no significant differences after false discovery rate correction. Multivariate analysis indicated that FPC status was not an independent prognostic factor (hazard ratio 1.73, p = 0.084).
[CONCLUSIONS] Transcriptomic profiles and HRD status were similar between patients with FPC and patients with non-FPC. A spectrum of GLMs was observed in both groups, suggesting that hereditary risk variants are not exclusive to FPC and underscoring the importance of germline testing in all patients with PC.
[METHODS] We retrospectively analyzed 111 resected PCs, including 13 patients with FPC (11.8%) and 98 with non-FPC (88.2%). Whole-exome sequencing targeted 151 cancer-related genes, with parallel gene expression profiling. GLMs were assessed by ClinVar and in silico tools. Homologous recombination deficiency (HRD) scores, COSMIC signatures, immune deconvolution, and survival were compared.
[RESULTS] Patients with FPC and non-FPC were comparable in age, sex, tumor stage, and receipt of adjuvant chemotherapy. ClinVar-annotated GLMs were found in 2/13 patients with FPC (15.4%) and 4/98 patients with non-FPC (4.1%). FPC cases more often carried pancreatitis-associated variants (SPINK1, CFTR), whereas non-FPC included HRR-related variants (PALB2, FANCG). When potentially pathogenic HRR-related variants were considered together, prevalence was similar (23.1% vs. 12.2%, p = 0.380). HRD scores did not differ (median 22 vs. 19, p = 0.591), and high HRD scores (≥ 42) were observed only in two non-FPC cases, including one with PALB2. Differential expression analysis revealed no significant differences after false discovery rate correction. Multivariate analysis indicated that FPC status was not an independent prognostic factor (hazard ratio 1.73, p = 0.084).
[CONCLUSIONS] Transcriptomic profiles and HRD status were similar between patients with FPC and patients with non-FPC. A spectrum of GLMs was observed in both groups, suggesting that hereditary risk variants are not exclusive to FPC and underscoring the importance of germline testing in all patients with PC.
MeSH Terms
Humans; Pancreatic Neoplasms; Male; Female; Middle Aged; Retrospective Studies; Prognosis; Germ-Line Mutation; Survival Rate; Aged; Biomarkers, Tumor; Follow-Up Studies; Adult; Recombinational DNA Repair; Exome Sequencing; Genomics; Carcinoma
같은 제1저자의 인용 많은 논문 (5)
- Waist-to-Height Ratio as a Predictor Complementary to BMI for Postoperative Pancreatic Fistula After Pancreatoduodenectomy for Periampullary Tumors.
- Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma.
- Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers.
- ASO Author Reflections: Genomic Features of Familial and Sporadic Pancreatic Cancer.
- A computational model of inflammation reveals crosstalk among energy metabolism, oxidative stress, insulin, and cytokines in hepatocytes during early MASLD progression.